Loading
MB
Mustang Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Jin David, was filed 30 Dec 2025.
Mustang Bio, Inc.: what insiders have been doing
This page follows insider dealings at Mustang Bio, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 22 October 2026, brought 5 filings signed by 5 insiders.
Both sides are active: 1 purchase worth €202 and 2 sales worth €205, from 1 insider and 2 insiders respectively. The net balance comes to €3 on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a sale of €202 from Herskowitz Neil, disclosed on 30 December 2025. The buyers include 1 senior executive.
The last purchase on record was published on 30 December 2025, which is 298 days ago. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 5 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Over the whole record (from 2017), the tally stands at 23 purchases and 12 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -1.9 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
104
Thresholds
n/a
Buy Volume
€2M
23 ops. · all time
Sell Volume
€108,014
12 ops. · all time
Who traded when
BuySaleAdam J. Chill1 sale
David Jin1 buy
Neil Herskowitz1 sale
Since the insiders bought
- -61.0%Entry US$0.98 · Close 21 Oct 2026 US$0.38
- -81.7%Entry US$224.50 · Close at T+365 US$41.00
- -81.7%Entry US$224.50 · Close at T+365 US$41.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.37
Analyst consensus
Income statement
EBITDA-US$2.4M
Net income-US$1.9M0.0% margin
Valuation
P/Book0.4x
Beta2.09
Balance sheet & cash
Market capUS$2.8M
Free Cash Flow-US$5.3M
Profitability & ownership
ROE-58.1%
ROA-15.4%
% insiders8.0%
% institutions9.9%
Last declaration on 27 April 2026
Declarations104 total
19 shares@ US$0.750.0003% mcap0.0% of flowCOMMON STOCKSEC:0001104659-26-049430:0
278,385 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001429260-26-000002:0
247 shares@ US$0.962100.0% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-25-125233:0
4 shares@ US$0.9548100.0% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-25-125232:0
247 shares@ US$0.962100.0% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-25-125227:0
Canonical exit: 30 Mar 2026 (T+90)
59,334 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001429260-25-000004:0
27 shares@ US$1.240.0% of flowCOMMON STOCKSEC:0001104659-25-040237:0
67,806 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001415889-25-009620:0
575,191 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-076298:0
1,572 shares@ US$4.21Common StockSEC:0001104659-24-068409:1
1,248 shares@ US$12.152.0% of flowCommon StockSEC:0001104659-24-068409:0
1,396 shares@ US$0.350.1% of flowCommon StockSEC:0001104659-24-068411:0
419,092 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-000859:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079112:0
5,000 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079110:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079117:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079111:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079114:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079118:0
5,000 shares@ US$0.51640.6% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040932:2
Canonical exit: 12 Dec 2022 (T+90)
5,000 shares@ US$0.51640.1% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040934:2
Canonical exit: 12 Dec 2022 (T+90)
71,664 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040932:1
61,000 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040934:1
71,664 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040924:0
71,664 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040927:0
25 of 104 declarations
About Mustang Bio, Inc.
Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company listed on the NASDAQ in the United States. The company is focused on developing cell and gene therapies aimed at difficult-to-treat cancers, placing it squarely in the high-risk, high-upside segment of small-cap biotechnology. Mustang Bio was incorporated in Delaware on March 13, 2015, and was founded by Fortress Biotech, giving it an early strategic and financing framework through which to build its pipeline. Today, the company identifies its headquarters in Waltham, Massachusetts, a location that fits well within the US East Coast biopharma ecosystem.
Its business model is centered on translational research and clinical development rather than commercial sales. Mustang Bio’s platform has historically included CAR-T programs and other precision-medicine approaches for oncology, with work spanning hematologic malignancies, solid tumors and, in some cases, rare genetic diseases. The company remains a development-stage entity and does not have an approved product on the market. For equity investors, that means the story is primarily about clinical milestones, regulatory progress, funding capacity and dilution risk rather than current operating earnings.
Read moreShow less
In competitive terms, Mustang Bio operates in a crowded field dominated by larger biotech players, academic spinouts and partnership-driven platforms with deeper capital resources. Its potential advantage lies in the selective acquisition and licensing of promising technologies from leading research institutions, allowing it to focus on value creation through targeted development rather than broad commercialization. At the same time, the business remains exposed to the usual biotechnology risks: trial failures, manufacturing complexity, regulatory uncertainty and persistent capital needs.
Recent corporate developments have been important for market perception. In early 2025, Mustang Bio addressed Nasdaq listing-compliance issues related to minimum bid price requirements and later announced it had regained compliance. The company also completed a 1-for-50 reverse stock split in January 2025 and raised additional capital during 2025 to support operations. In July 2025, Mustang Bio announced that the US FDA granted orphan drug designation to MB-101 for astrocytomas and glioblastoma, a notable regulatory milestone that may support the long-term investment case if clinical data continue to progress positively. Overall, MBIO remains a speculative NASDAQ-listed US biotech story whose valuation is driven by pipeline execution, financing discipline and milestone delivery.
